Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 25Leukemia, Myeloid, Acute 25Breast Neoplasms 18Prostatic Neoplasms 16Myelodysplastic Syndromes 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Multiple Myeloma 14Lung Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Burkitt Lymphoma 11Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Myelomonocytic, Chronic 9Ovarian Neoplasms 8Melanoma 8Stomach Neoplasms 7Lymphoma, T-Cell 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, B-Cell 6Carcinoma, Renal Cell 6Myeloproliferative Disorders 5Mouth Neoplasms 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Fallopian Tube Neoplasms 5

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hereditary leiomyomatosis and renal cell cancer × Biopsy × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡